Raptim Research

Raptim Research Pvt Ltd is a global contract research organization established in India in 2005. It offers comprehensive clinical development and laboratory services to pharmaceutical and biotechnology companies worldwide. The company specializes in bioavailability/bioequivalence studies, clinical trials across all phases (I-IV), bioanalytical testing, post-marketing surveillance studies and regulatory support. In March-April of 2025 the US FDA identified significant data integrity concerns with certain bioequivalence studies conducted by Raptim—specifically falsification of some in vitro data—which has led to rejection or required repetition of affected drug applications relying on these results. Despite this setback and ongoing regulatory scrutiny regarding past study conduct, there’s no indication that the company has ceased operations.